X4 Pharmaceuticals Reports Director Departure and Shareholder Votes

X4 Pharmaceuticals Inc. reported the departure of a director and detailed the outcomes of matters submitted to a vote of security holders in a Form 8-K filed with the SEC on May 13 2026.

The filing covers Item 5.02 on the departure or election of directors or principal officers and Item 5.07 on the submission of matters to a vote of security holders along with Item 9.01 exhibits per the SEC EDGAR record for CIK 0001501697.

X4 Pharmaceuticals a publicly traded company focused on rare disease therapeutics now operates with one fewer board member following the reported departure. The scope of the shareholder vote encompassed standard annual meeting items including director elections and any other proposals put before holders of the company's common stock though exact vote tallies and proposal counts are contained in the exhibits to the filing.

The operational change consists of the loss of the named director whose service ended on or before the May 13 2026 filing date. Prior to the departure the board maintained its prior composition; the new state reflects the reduced membership effective immediately upon the departure date cited in the filing.

The company must update its disclosures as required under SEC rules including any subsequent Form 8-K or proxy amendments if additional elections occur to fill the vacancy.

Downstream the departure requires the company to identify any disagreements with the director if applicable and to file any related board committee changes. The shareholder vote results now become part of the official record triggering incorporation into future proxy statements and potentially influencing governance ratings or activist investor calculations.

Markets and regulators receive formal notice through the 8-K which must be referenced in any subsequent securities offerings or filings under the Securities Exchange Act.

This filing constitutes the primary SEC record for the events and follows standard practice for Item 5.02 and 5.07 disclosures by public companies. X4 Pharmaceuticals last reported similar governance updates in prior 8-K filings tied to its annual shareholder meetings and clinical development milestones.